Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Roti patents



      

This page is updated frequently with new Roti-related patent applications.




Date/App# patent app List of recent Roti-related patents
04/28/16
20160115246 
 Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9 patent thumbnailnew patent Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9
The present invention provides methods and compositions for inhibiting atherosclerotic plaque formation in a subject. In certain embodiments, the methods of the present invention comprise selecting a subject who has, or is at risk of developing, atherosclerosis, and administering to the subject a pharmaceutical composition comprising a proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitor.
Regeneron Pharmaceuticals, Inc.


04/28/16
20160113968 
 Hypoxia-cultured mesenchymal stem cells for treating atherosclerotic lesions patent thumbnailnew patent Hypoxia-cultured mesenchymal stem cells for treating atherosclerotic lesions
A method and a pharmaceutical composition for treating an atherosclerotic lesion are provided, including administering a subject in need thereof a therapeutically effective amount of a composition comprising hypoxia-cultured mscs obtained by culturing auto- or allo-mscs under low oxygen conditions.. .
National Yang-ming University


04/28/16
20160113675 
 Intravascular catheter having a cantilevered expandable incising portion patent thumbnailnew patent Intravascular catheter having a cantilevered expandable incising portion
An intravascular device is provided having a catheter tube and an expandable portion including a plurality of struts supported in a cantilevered fashion so as to be splayed open when in an opened position. An incising element is provided on at least one of the struts and has a sharpened edge for creating an incision in atherosclerotic material located within a blood vessel when the expandable portion is in the opened position..

04/21/16
20160106851 
 Groundbreaking platform technology for specific binding to necrotic cells patent thumbnailGroundbreaking platform technology for specific binding to necrotic cells
A system comprising a targeting molecule for binding necrotic cells; to the system for use as a medicament; to use of the system for diagnosis; to the system for use in treatment of diseases involving necrotic cell death, to a dosage comprising the system; to a method for determining localization of the composition within a sample using said system; and, to a method for treatment of cancers and/or diseases involving necrotic cell death using said system. In particular the invention relates to compositions targeting necrotic cells..

04/21/16
20160106811 
 Method for repairing neurodegeneration patent thumbnailMethod for repairing neurodegeneration
The present invention provides for treating neurodegeneration caused by nerve compression syndrome or entrapment neuropathy comprising administering human acidic fibroblast growth factor (afgf), fibrinogen, aprotinin and divalent calcium ions to a subject in need thereof.. .

04/14/16
20160101165 
 Compositions and kits for enzymatic debridement and methods of using the same patent thumbnailCompositions and kits for enzymatic debridement and methods of using the same
A debridement enzyme for necrotic tissue is described that is not dependent upon proteolytic enzymatic activity but instead utilizes the amylase family of enzymes. The amylases (α-, β-, γ-amylase) are noted for the cleavage of the α-glycosidic bonds of polysaccharides, yielding lower molecular weight carbohydrate/sugar fragments.

04/14/16
20160100879 
 Electrical ablation devices and methods patent thumbnailElectrical ablation devices and methods
A computer-implemented system for delivering energy to tissue having a necrotic threshold may generally comprise an electrode array comprising a plurality of electrodes, a central electrode positioned intermediate the plurality of electrodes, and a controller configured to not only apply a first sequence of electrical pulses to the electrode array to induce thermal heating in the tissue and reduce the necrotic threshold of the tissue but also apply a second sequence of electrical pulses to the central electrode to induce cell necrosis in the tissue by irreversible electroporation. Electrical ablation devices and methods of using the same are also described herein..

04/07/16
20160095876 
 Composition and kits for inhibition of pathogenic microbial infection and methods of using the same patent thumbnailComposition and kits for inhibition of pathogenic microbial infection and methods of using the same
Antimicrobial polymer coating formulations are prepared that protect biological surfaces by treating, reducing, ameliorating, preventing or inhibiting pathogenic microorganism ingress to a human or animal host, reducing the potential for infection, particularly by necrotizing fasciitis originating microorganisms, through use of an polymer coating barrier containing antimicrobial agents that facilitates sustained release of biocidal agents active against such opportunistic microorganisms. Such formulations are effective for inhibiting microbial ingress pertaining to soft tissue and skin tears, abrasions, punctures and surgical wounds, and can be used as in water environments and as a skin protectant sunscreen and insect repellent..
Rochal Industries, Llp


03/31/16
20160089252 
 Extravascular protective stent patent thumbnailExtravascular protective stent
An extravascular protective stent includes a booster, a hollow protective tube and a hollow separator all sequentially arranged, wherein the side wall of the protective tube is provided with a protective notch parallel to the central axis of the protective tube and extending through two ends of the protective tube. During use of the separator and the protective tube when an internal carotid artery is exposed after a common carotid artery bifurcation is separated via a submandibular incision, the separator and the protective tube wrap the internal carotid artery in sequence, allowing the separating notch and the protective notch to face outward, and the closed wall thereof to face inward and directly face the surgery direction, such that a surgeon can thoroughly excise diseased tissue in surgery and avoid hemorrhage caused by accidentally injuring the internal carotid artery during the surgery, and improve the surgical efficacy..

03/24/16
20160082264 
 Implantable device including a stimulation lead for bioimpedance measurement patent thumbnailImplantable device including a stimulation lead for bioimpedance measurement
An implantable device includes a lead, for example for neurostimulation of the vagus nerve. The lead includes a series of stimulation electrodes and a series of external electrodes for bioimpedance measurements on blood flow located in the same region, for example on the carotid artery.
Sorin Crm Sas


03/24/16
20160082051 

Use of sea cucumber glycosaminoglycan in preparing medicine for prevention and treatment of thromboembolic disease


The present invention discloses use of sea cucumber glycosaminoglycan in the preparation of drugs. In particular, the present invention relates to use of medical use of sea cucumber glycosaminoglycan, and more particularly to use of depolymerized sea cucumber glycosaminoglycan or natural molecular segments of sea cucumber glycosaminoglycan with a weight average molecular weight greater than 54,500 da in the preparation of a drug for the prevention and treatment of thromboembolic diseases.
Heilongjiang Hongdoushan Pharmaceutical Co., Ltd.


03/24/16
20160082011 

Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome


The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain dpp-4 inhibitor, as well as to the use of a certain dpp-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and/or nephrotic syndrome.. .
Boehringer Ingelheim International Gmbh


03/24/16
20160081848 

Cooling elements with bands


A kit for cooling the blood in the carotid arteries includes a cervical immobilization collar and a cooling element. The cooling element may include a body-facing panel attached on a body-facing surface to a lining layer, an outward-facing panel, and cooling material disposed between the body-facing panel and the outward facing panel.
Cryothemic Systems, Inc.


03/24/16
20160081643 

X-ray ct device and processing method


The present invention is capable of distinguishing four types or more of substances such as air, water (soft tissues), contrast medium, and bones (calcification) to diagnose progress of atherosclerotic sites using dual energy imaging. A subject is imaged with two types of different tube voltages and an image obtained by image reconstruction is binarized to carry out a reprojection process; thereby, the distance of penetration of air is estimated, the contribution of air in measurement projection data is determined, and the amount of reduction by the air is deducted from the projection data so as to enable distinction between four or more substances such as air, water (soft tissues), contrast medium, and bones (calcification)..
Hitachi Medical Corporation


03/24/16
20160081561 

Noninvasive arterial condition detecting method, system, and non-transitory computer readable storage medium


A noninvasive arterial condition detecting system includes a processing device and an electronic stethoscope configured for auscultating carotid artery to receive sound signals. The processing device is connected to the electronic stethoscope.
National Central University


03/17/16
20160074677 

Methods and devices to modulate the autonomic nervous system via the carotid body or carotid sinus


In some embodiments, sympathetic nerves surrounding arteries or leading to organs are targeted with energy sources to correct or modulate physiologic processes. In some embodiments, different types of energy sources are utilized singly or combined with one another.
Kona Medical, Inc.


03/17/16
20160074473 

Effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties


The present invention relates to peptide-phospholipid formulations, methods of generating these formulations and methods of administering these formulations for treatment. The present disclosure also provides methods for increasing cholesterol efflux, inducing anti-atherosclerotic activity, increasing pre-β hdl, inducing anti-inflammatory activity, inhibiting cytokine release (including cytokines tnf-α, il-1β, and/or il-6 or a combination thereof) and increasing cholesterol mobilization and/or esterification by administering the peptide-phospholipid formulations disclosed..
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


03/17/16
20160074466 

Angiotensins for treatment of fibrosis


The present invention provides, among other things, methods and compositions for treating or preventing fibrotic diseases, disorders or conditions based on angiotensin (1-7) polypeptides, and analogs or derivatives thereof. In some embodiments, compositions and methods for treating or preventing pulmonary fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (copd), asthma, cystic fibrosis, kidney fibrosis, liver fibrosis, systemic sclerosis, post-surgical adhesions, accelerating wound healing, and reducing or preventing scar formation are provided..
Tarix Pharmaceuticals Ltd.


03/17/16
20160074457 

Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome


Pharmaceutical/dietary supplements and food ingredient(s) derived from sphaeranthus indicus are used for controlling or treating a metabolic disorder. The supplements and food ingredient(s) are selected from sphaeranthus indicus extract(s), fraction(s), active compound(s) and phytochemical(s) or mixtures thereof and their compositions, preferably in combination with at least one component selected from the extract(s), fraction(s), active compound(s) and phytochemical(s) or mixtures thereof derived from garcinia mangostana.
Laila Nutraceuticals


03/17/16
20160074422 

Mucus strengthening formulations to alter mucus barrier properties


The present technology relates to compositions and methods that strengthen mucus barriers, e.g., reduce the permeability of the mucus barriers. In some embodiments, the compositions include a model bile and a lipid mixture, wherein the model bile includes at least one salt and a lecithin.
Northeastern University


03/10/16
20160069868 

Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrosis


The present invention relates to methods and assays for identifying agents useful in the treatment of fibrotic diseases, in particular diseases related to fibroblast migration and differentiation. The invention provides polypeptide and nucleic acid targets, sirna sequences based on these targets and antibodies against the targets.
Galapagos Nv


03/10/16
20160068487 

Novel compounds as diacylglycerol acyltransferase inhibitors


This invention relates to novel compounds which are inhibitors of acyl coenzyme a: diacylglycerol acyltransferase 1 (dgat-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to dgat-1 dysfunction or where modulation of dgat-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (type 1, type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as mycocardial, renal and liver fibrosis, hepatitis c virus infection and acne or other skin disorders.. .
Glaxosmithkline Llc


03/10/16
20160068467 

Amphiphilic macromolecules and methods of use thereof


Or a salt thereof, wherein a, x, y, z and r1 have any of the values defined in the specification, and methods of use thereof. For example, certain embodiments of the invention provide a method for inhibiting atherosclerosis or atherosclerotic development in a mammal, comprising administering to the mammal an effective amount of a compound of formula (i), or a pharmaceutically acceptable salt thereof..

03/10/16
20160067247 

Novel use


The present invention is directed to compounds or pharmaceutically acceptable salts thereof for use in the treatment of fibrotic diseases such as idiopathic pulmonary fibrosis (ipf).. .
Glaxosmithkline Intellectual Property (no.2) Limited


03/03/16
20160061846 

Method for evaluating atherosclerotic lesion, and kit


The present invention provides a method and a means for evaluating atherosclerotic lesions by identifying a protein (marker protein) group, the expression level of which varies according to the progression of the atherosclerotic lesion, and using the proteins. Specifically, the present invention relates to a method for evaluating atherosclerotic lesions, comprising the steps of detecting a marker protein exhibiting an expression pattern (expression variation) characteristic at a specific disease stage of atherosclerotic lesions in a subject, and evaluating the atherosclerotic lesions in the subject based on the detection result..
National University Corporation Hokkaido University


03/03/16
20160061845 

Compositions and methods for treating steroid resistant nephrotic syndrome and/or steroid sensitive nephrotic syndrome


Disclosed are methods of determining whether a patient diagnosed with nephrotic syndrome has steroid sensitive nephrotic syndrome (ssns) or steroid resistant nephrotic syndrome (srns) by determining the levels of one or more biomarkers in a biofluid from the patient. Also disclosed are methods of treating a patient diagnosed with nephrotic syndrome, and kits and substrates related to the disclosed methods..
Children's Hospital Medical Center


03/03/16
20160060626 

Modulation of angiopoietin-like 3 expression


Provided herein are methods, compounds, and compositions for reducing expression of an angptl3 mrna and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal.
Isis Pharmaceuticals, Inc.


03/03/16
20160058368 

System and imaging biomarkers indicative of caridac thermal ablation lesions


Described here are systems and methods for visualizing thermal ablation lesions by imaging specific chemical compounds that are created during thermal ablation procedures, such as cardiac ablation procedures. When a cardiac ablation procedure is performed, a central area of coagulative necrosis is created at the treatment site.
Sunnybrook Research Institute


02/25/16
20160054304 

Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrotic diseases


The present invention relates to methods and assays for identifying agents useful in the treatment of fibrotic conditions. The invention provides polypeptide and nucleic acid targets, sirna sequences based on these targets and antibodies against the targets.
Galapagos Nv


02/18/16
20160046768 

Method for preparing polyamideimide fibrid


The invention provides a method for preparing a polyamideimide fibrid, characterized by comprising the following specific steps: step 1: reacting diamine monomer with trimellitic anhydride chloride in an aprotic polar solvent in the presence of a catalyst to obtain a polyamide acid polymer, and carrying out chemical cyclization dehydration on the polyamide acid polymer to obtain a polyamideimide polymer solution; step 2: diluting the polyamideimide polymer solution, adding the diluted polyamideimide polymer solution and precipitation solution to a precipitation machine, and mixing to obtain a polyamideimide fibrid suspension; and step 3: washing, filtering and drying the polyamideimide fibrid suspension to obtain a polyamideimide fibrid. The invention is characterized by simple process, the size and shape of the fibrid are easy to be controlled, and the fibrid can be directly used to prepare high performance paper..
Jiangsu Juxian Synthetic Material Co., Ltd.


02/18/16
20160045741 

Vagus nerve and carotid baroreceptor stimulation system


Systems and methods are provided for delivering vagus nerve stimulation and carotid baroreceptor stimulation to patients for treating chronic heart failure and hypertension. The vagus nerve stimulation and carotid baroreceptor stimulation therapies may be provided using a single implantable pulse generator, which can coordinate delivery of the therapies..
Cyberonics, Inc.


02/11/16
20160039736 

Substituted aromatic compounds and related the treatment of fibrosis


Or a pharmaceutically acceptable salt thereof, wherein a is c5 alkyl, c6 alkyl, c5 alkenyl, c6 alkenyl, c(0)-(ch2)n-ch3 or ch(oh)—(ch2)n-ch3 wherein n is 3 or 4; r1 is h, f or oh; r2 is c5 alkyl, c6 alkyl, c5 alkenyl, c6 alkenyl, c(0)-(ch2)n-ch3 or ch(oh)—(ch2)n-ch3 wherein n is 3 or 4; r3 is h, f, oh or ch2ph; r4 is h, f or oh; q is 1) (ch2)mc(0)oh wherein m is 1 or 2, 2) ch(ch3)c(0)oh, 3) c(ch3)2c(0)oh, 4) ch(f)—c(0)oh, 5) cf2-c(0)oh, or 6) c(0)-c(0)oh; and compositions comprising the same and the method using the same for the prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis, renal fibrosis, pancreas fibrosis, systemic sclerosis, cardiac fibrosis or macular degeneration.. .

02/11/16
20160038395 

Composition for facial contouring comprising mixture of botulinum toxin and air and facial contouring using the same


The present invention provides a composition for facial contouring, comprising a mixture of botulinum toxin and air, and a method of facial contouring using the same. When the mixture of botulinum toxin and air is injected into an smas layer, the mixture strengthens the smas layer and draws back the galea aponeurotica to effectively lift up the face or change the facial contour, thus effectively enhancing the effect of facial contouring..

02/04/16
20160030475 

Use of a clay product or a clay blend product to decrease the effects of bacterial disease in shrimp


Applicants have examined two clostridium species, clostridium difficile and clostridium perfringens, and found that clays can adsorb the toxin produced by both and that a clay blended product can decrease the effects of a prominent in chickens and known as necrotic enteritis, that is caused by c. Perfringens.
Oil-dri Corporation Of America


02/04/16
20160030472 

Xenon-based anesthetic gas composition usable during an endarterectomy involving the clamping of the carotid artery


A xenon-based anesthetic gas to be used, via inhalation, to maintain or preserve cerebral perfusion during an endarterectomy involving the clamping of the carotid artery in a mammal under general anesthesia. The xenon is preferably used in combination with at least one injectable anesthetic morphine agent such as remifentanil, sulfentanil, fentanyl, and alfentanil.
Air Liquide Santé (international)


02/04/16
20160030153 

Embolic protection during percutaneous heart valve replacement and similar procedures


Various devices are described to provide filtering of flow from the aorta to the left carotid artery and the right carotid artery. The filters can be brought into a desired position through one or more peripheral arteries.
Lumen Biomedical, Inc.


02/04/16
20160030001 

Helmet apparatus and system with carotid collar means on-boarded


Apparatus for helmeting with carotid collars works in conjunction with a transcranial doppler, phased array photoacoustic device to transmit a first energy to a region of interest at an internal site of a subject to produce an image and blood flow velocities of a region of interest by outputting an optical excitation energy to said region of interest and heating said region, causing a transient thermoelastic expansion and produce a wideband ultrasonic emission. Systems integrate and register the signals for use in, for example, acute stroke care..

01/28/16
20160025743 

Method for the early detection of renal disease using proteomics


A method for the detection of an early biomarker for assessing a change in renal status in a mammalian subject following a renal event. The method typically includes the steps of (a) providing a body fluid sample obtained from a mammalian subject; (b) analyzing the molecular weight of the proteins in the sample using proteome analysis; and (c) identifying the presence of a protein in the sample selected from the group consisting of a 6.4 kda protein, a 28.5 kda protein, a 33 kda protein, a 44 kda protein, a 67 kda protein, and combinations thereof.
Children's Hospital Medical Center


01/28/16
20160024577 

Methods for identifying stem cells based on nuclear morphotypes


Methods for identifying stem cells and other cells specific to embryogenesis and carcinogenesis, classifying tissue samples, diagnosing precancerous and cancerous or atherosclerotic lesions, testing the value of anticancer agents, discovering macromolecules specifically expressed in particular cell types, using stem cells in restorative tissue therapy as well as methods for preparing tissue samples so heteromorphic nuclear morphotypes remain intact are disclosed.. .
Massachusettes Institute Of Technology


01/28/16
20160024213 

Anti-macrophage mannose receptor single variable domains for use in cardiovascular diseases


The disclosure relates to the field of cardiovascular diseases. In particular, immunoglobulin single variable domains directed against macrophage mannose receptor (mmr) are provided that can be used in the diagnosis, prognosis and/or monitoring of cardiovascular diseases or as therapeutics.
Vrije Universiteit Brussel


01/28/16
20160023983 

Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis,skin fibrosis and cardiac fibrosis


The present invention relates to substituted aromatic compounds for use in prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis, where the compound has the following formula: or a pharmaceutically acceptable salt thereof, wherein a is c5 alkyl, c6 alkyl, c5 alkenyl, c6 alkenyl, c(o)—(ch2)n—ch3 or ch(oh)—(ch2)n—ch3 wherein n is 3 or 4; r1 is h, oh or f; r2 is h, oh, f or ch2—oh; r3 is h, oh, f or ch2ph; r4 is h, oh or f; q is 1) (ch2)mc(o)oh wherein m is 1 or 2, 2) ch(ch3)c(o)oh, 3) c(ch3)2c(o)oh, 4) ch(f)—c(o)oh, 5) cf2—c(o)oh, or 6) c(o)—c(o)oh.. .
Prometic Biosciences Inc.


01/28/16
20160022377 

Combined use of ultrasound with nickel titanium endodontic file in endodontic procedure


The root canal is cleaned by moving the working portion of the file within the root canal so that the working portion of the file cuts or abrades tissue within the root canal. Ultrasonic energy is applied to the file, tooth, or both in order to assist in breaking up and removing necrotic tissue in the root canal during cleaning.

01/21/16
20160015548 

Patient treatment system


A patient treatment system for treating a patient includes a cervical collar having a first opening located over a trachea of the patient and a second opening located over a carotid artery of the patient. An aid is disposed in the second opening and includes a base having a curved surface; the base is disposed proximal to a neck of the patient over the carotid artery.

01/14/16
20160009725 

Pyrrolo- and pyrazolo-triazolodiazepines as bet-protein inhibitors for treating hyperproliferative diseases


In which x, y, n, m, r1, r2, r3, r4 and r5 are each as defined in the description, to intermediates for preparation of the inventive compounds, to pharmaceutical compositions comprising the inventive compounds, and to the prophylactic and therapeutic use thereof for hyperproliferative disorders, especially for tumour disorders. Also described is the use of the compounds according to the invention as bet protein inhibitors for benign hyperplasias, for atherosclerotic disorders, for sepsis, for autoimmune disorders, for vascular disorders, for viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for male fertility control..

01/14/16
20160008311 

Oleacein for treating or preventing diseases resulting from atherosclerotic plaques


A description and explanation is provided of the use of oleacein, especially this obtained from ligustrum vulgare l., in the manufacturing of a preparation for the treatment and prevention of diseases that are consequences of the atherosclerotic plaque degradation. Such diseases include in particular those selected from the following group: ischemic brain stroke, heart attack and ischemic heart disease..
Warszawski Uniwersytet Medyczny


01/07/16
20160003808 

Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition


The present invention relates to methods and assays for identifying agents useful in the treatment of diseases associated with epithelial mesenchymal transition (emt), in particular fibrotic diseases and cancer. The invention provides polypeptide and nucleic acid targets, sirna sequences based on these targets and antibodies against the targets.
Galapagos Nv


01/07/16
20160002354 

Antibodies to bone marrow stromal antigen 1


The invention provides antibodies which bind to the adp-ribosyl cyclase 2. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided.
Oxford Biotherapeutics Ltd


01/07/16
20160000499 

Endovascular catheters for carotid body ablation utilizing an ionic liquid stream


Methods and endovascular catheters for assessing, and treating patients having sympathetically mediated disease, involving augmented peripheral chemoreflex and heightened sympathetic tone by reducing chemosensor input to the nervous system via transmural carotid body modulation using a catheter with an ionic liquid stream electrode.. .
Cibiem, Inc.


12/31/15
20150376623 

Antisense oligonucleotides directed against connective tissue growth factor and uses thereof


This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.. .
Isis Pharmaceuticals, Inc.


12/31/15
20150376204 

Alpha helix mimetic compositions for treating cancer and other cbp/catenin-mediated diseases and conditions


Alpha-helix mimetic structures and compounds represented by the formula (i) wherein the general formula and the definition of each symbol are as defined in the specification, a compound relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed..
Prism Biolab, Co., Ltd.


12/31/15
20150376196 

4-substituted pyrrolo- and pyrazolo-diazepines


Are described, in which x, y, n, m, p, r1, r2, r3, r4 and r5 are each as defined in the description, as are pharmaceutical compositions comprising the inventive compounds, and the prophylactic and therapeutic use thereof in the case of hyperproliferative disorders, especially in the case of neoplastic disorders. Also described is the use of the inventive compounds as bet protein inhibitors in benign hyperplasias, in atherosclerotic disorders, in sepsis, in autoimmune disorders, in vascular disorders, in viral infections, in neurodegenerative disorders, in inflammatory disorders and in male fertility control..

12/24/15
20150368262 

Alpha helix mimetics and methods relating thereto


Alpha-helix mimetic structures and compounds represented by the formula (i) wherein the general formula and the definition of each symbol are as defined in the specification, a chemical library relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed..
Prism Biolab Co., Ltd.


12/24/15
20150366581 

Percutaneous tools for minimally invasive access to the carotid sheath for vagus nerve stimulation


Various aspects describe a lead delivery system for percutaneous introduction of a lead to a stimulation site near a neural target, such as the vagus nerve for nerve stimulation. The lead delivery system may include a needle assembly having a needle adapted to cut through tissue and provide initial access into the carotid sheath.
Cardiac Pacemakers, Inc.


12/24/15
20150366239 

Production fish feed enriched with polar lipids and method to enrich farmed fishes


The present disclosure relates to the production of fish feed with olive ingredients intended for farmed freshwater and saltwater fish, and the aquaculturing of freshwater and saltwater fish which are fortified or enriched through their feeding with ingredients derived from olive processing byproducts. The invention also relates to the fortified or enriched fish as such.
Nireus Aquaculture S.a


12/17/15
20150360010 

Carotid sheath with entry and tracking rapid exchange dilators and use


Dilators and sheaths for use in minimally invasive vascular therapy are disclosed. In some embodiments, the dilators include a slot that accesses a guidewire lumen within the dilator.
Fischell Innovations, Llc


12/17/15
20150359905 

Composition of anti-endo180 antibodies and methods of use for the treatment of cancer and fibrotic diseases


The present invention provides antibodies or antigen-binding fragments thereof that specifically bind the endo180 polypeptide and are internalized thereby, to conjugates comprising the molecules, to compositions comprising the antibodies and conjugates and to methods of using the same for delivery of therapeutic agents to cells that express the endo180 polypeptide on the surface of the cell for treating cell proliferative diseases or disorders and fibrosis, and for controlling (modulating) tumor progression.. .
Quark Pharmaceuticals, Inc.


12/17/15
20150359848 

Methods and related kits for treating and regenerating tooth pulp and periapical tissues in a mammal


In one embodiment, a method of regenerating tooth pulp in a mammal is provided. The method comprises removing at least a portion the existing tooth pulp of a mammal and adding amelogenin protein to the existing tooth pulp of the mammal to regenerate tooth pulp in a mammal.
University Of Southern California


12/17/15
20150359207 

Animal model for evaluating performance of hemostatic agent for inducing hemorrhage in common carotid artery or superior sagittal sinus, and use thereof


The present invention relates to an animal model for evaluating hemostatic performance, and the use thereof, and more particularly, to an animal model for evaluating the performance of a hemostatic agent, which has hemorrhage induced in the common carotid artery (cca) or superior sagittal sinus (sss) of the animal, a method of screening a hemostatic agent using the animal model, and a method of evaluating the effect of a hemostatic agent using the animal model. The animal model according to the present invention makes it possible to observe the hemostatic effect of a hemostatic agent in a rapid and accurate manner without causing side effects.
Inno Therapy Inc.


12/10/15
20150352065 

Methods of treatment of fibrosis and cancers


The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethyl-methyloxyphenyl]prop-2-en-1-one for treating fibrotic diseases and cancers.. .
Genfit


12/10/15
20150352038 

A dosage form for administering an active principle for accelerated sleep induction and/or for treating sleep disorders and/or for treating a central nervous system disorder


A dosage form for oral administration, via the mucous membranes, of an active principle for accelerated sleep induction and/or for treating sleep disorders and/or for treating a central nervous system disorder, the active principle being lipophilic or amphiphilic and being in a dissolved state that is stable and complete in a hydro-alcoholic solution having 35% to 70% by weight of ethanol and 30% to 65% by weight of water, generating nanostructures of the active principle under consideration within the hydro-alcoholic solution, thereby enabling the active principle to cross the blood-brain barrier, the active principle being in base and/or salt form and belonging to the chemical families of sleep inducers or modulators of lipophilic or amphiphilic type and of molecular weight that is less than 1000 da, the active principle being selected from the families of imidazopyridines, including zolpidem, the family of cyclopyrrolones, including eszopiclone, the family of pyrazolopyrimidines, including zaleplon, the family of benzodiazepines, including midazolam and brotizolam, the family of h1-antihistamine sedatives, including doxylamine and cyproheptadine, and/or the family of melatonin and melatonin agonists, including melatonin, ramelteon, and agomelatine, the volume of the hydro-alcoholic solution being less than or equal to 2 ml, and the active principle being present at a dosage that is less than or equal to 8 mg, all of the active principle being absorbed in transmucosal manner via the mucous membranes of the floor of the oral cavity, in particular via the gums/cheeks, via the gum area, via the cheeks, or under the tongue.. .

12/10/15
20150351782 

Systems and methods for treating atherosclerotic plaque


A system and method for treating atherosclerotic plaque. The system includes a first catheter including an expandable balloon and a second catheter including a lumen in fluid communication with a distal hole.
Boston Scientific Scimed, Inc.


12/03/15
20150344542 

Partial purification hydrophilic recombinant protein


The present invention relates to a method for partially purifying a hydrophilic recombinant protein from a host expressing a hydrophilic recombinant protein. The method includes: a solution acquisition step in which a dissolving solvent is added to the host expressing a hydrophilic recombinant protein so as to dissolve the host cell and an insoluble substance is separated therefrom so as to obtain a solution.
Spiber Inc.


12/03/15
20150344444 

Bet-protein-inhibiting dihydroxyquinoxalinones


In which a, x, r1, r2, r3, r4, r5, r6, r7 and n are each as defined in the description, to intermediates for preparation of the inventive compounds, to pharmaceutical compositions comprising the inventive compounds, and to the prophylactic and therapeutic use thereof in the case of hyperproliferative disorders, especially in the case of neoplastic disorders. This invention further relates to the use of bet protein inhibitors in viral infections, in neurodegenerative disorders, in inflammation disorders, in atherosclerotic disorders and in male fertility control..

12/03/15
20150342966 

Na/k-atpase ligand and uses thereof in wound healing


Methods and compositions for detecting, treating, characterizing, and diagnosing interstitial lung and/or fibrotic diseases are described.. .
The University Of Toledo


11/26/15
20150337037 

Human monoclonal antibodies against human chemokine receptor ccr6


Aspects of this invention include fully human antibodies or fragments thereof that bind specifically to human ccr6 receptor. Such antibodies or fragments thereof can be used to treat disorders involving over function of the ccr6 receptor, including cancers, inflammatory diseases and fibrotic diseases.
Msm Protein Technologies


11/19/15
20150329587 

Extraction hydrophilic recombinant protein


The present invention relates to a method for extracting a hydrophilic recombinant protein from a host expressing a hydrophilic recombinant protein. The method includes: a lysate acquisition step in which a dissolving solvent is added to the host expressing a hydrophilic recombinant protein so as to obtain a host cell lysate; and a step in which a diluting solvent is added to the host cell lysate obtained in the lysate acquisition step, an insoluble substance is separated from the obtained dilution, and a supernatant containing the hydrophilic recombinant protein is collected.
Spiber Inc.


11/19/15
20150328452 

Systems and methods for treating dyspnea, including via electrical afferent signal blocking


Systems and methods for treating a patient with dyspnea are disclosed. A method in accordance with a particular embodiment includes identifying the patient as suffering from dyspnea, and, based at least in part on identifying the patient as suffering from dyspnea, implanting an electrical signal delivery element within the patient in signal communication with an afferent neural pathway of a carotid body chemoreceptor.

11/12/15
20150322082 

Novel compounds as diacylglycerol acyltransferase inhibitors


This invention relates to novel compounds which are inhibitors of acyl coenzyme a: diacylglycerol acyltransferase 1 (dgat-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to dgat-1 dysfunction or where modulation of dgat-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (type 1, type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as myocardial, renal and liver fibrosis, hepatitis c virus infection and acne or other skin disorders.. .
Glaxosmithkline Llc


11/12/15
20150320904 

Tissue sealant in which collagen and fibrin are mixed, and preparing same


The present invention relates to a tissue sealant in which collagen and fibrin are mixed and to a method for preparing same. To this end, the method of the present invention comprises the steps of: mixing a first material using fibrinogen and aprotinin; mixing a second material using thrombin, calcium chloride, and collagen; and preparing a third material by mixing the first material and the second material.
Sewoncellontec Co., Ltd.


11/12/15
20150320706 

Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy


Administration of a 1-phenylalkanecarboxylic acid before, after, or a concurrently with a therapeutically effective amount of one or more of the following: (1) β-amyloid peptides level reducers, (2) pathogenic level tau reducers, (3) microtubule stabilizers, (4) agents capable or removing atherosclerotic plaques, (5) agents that lower circulating levels of β-amyloid and tau, (6) modulators of autophagy, (7) neurotransmitter levels regulators, (8) gaba(a) α5 receptor antagonists, and (9) additional agents that help maintain and/or restore cognitive function and functional deficits of ad, and/or slow down decline in cognitive functions and functional deficits in ad, is useful for prevention or therapeutical treatment of proteinopathies and/or neurodegenerative diseases.. .
Chiesi Farmaceutici S.p.a.


10/29/15
20150307556 

Template-fixed peptidomimetics with cxcr7 modulating activity


Wherein the single elements t or p are α-amino acid residues connected from the carbonyl (c═o) point of attachment to the nitrogen (n) of the next element in clockwise direction and wherein said elements, depending on their positions in the chain, are defined in the description and the claims have the property to act on the receptor cxcr7. Thus, these β-hairpin peptidomimetics can be useful in the treatment or prevention of diseases or conditions in the area of dermatological disorders, metabolic diseases, inflammatory diseases, fibrotic diseases, infectious diseases, neurological diseases, cardiovascular diseases, respiratory diseases, gastro-intestinal tract disorders, urological diseases, ophthalmic diseases, stomatological diseases, haematological diseases and cancer; or the mobilisation of stem cells..

10/29/15
20150306124 

Topical application of ivermectin for the treatment of dermatological conditions/afflictions


Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.. .
Galderma S.a.


10/29/15
20150306027 

Topical application of ivermectin for the treatment of dermatological conditions/afflictions


Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.. .
Galderma S.a.


10/22/15
20150299776 

Identification of a person having risk for atherosclerosis and associated disease by the person's gut microbiome and the prevention of such diseases


The present invention provides the use of metagenomics to identify a compositional or functional alteration of the gut metagenome related to atherosclerosis or atherosclerotic associated disease. Also provided are methods to identify a person having risk for atherosclerosis and associated diseases by determining the presence of specific bacterial groups or species and also metabolic functions in the person's gut microbiota and to use such information to develop a prevention or treatment strategy..
Metabogen Ab


10/22/15
20150299201 

Bet protein-inhibiting 5-aryl triazole azepines


In which r1, r2, r3 and r4 have the meanings given for the general formula (i), to pharmaceutical compositions comprising the compounds according to the invention, and to the prophylactic and therapeutic use thereof for hyperproliferative disorders, especially for neoplastic disorders. The present invention further relates to the use of bet protein inhibitors in viral infections, in neurodegenerative disorders, in inflammatory diseases, in atherosclerotic disorders and in male fertility control..

10/22/15
20150299138 

Novel compounds as diacylglycerol acyltransferase inhibitors


This invention relates to novel compounds which are inhibitors of acyl coenzyme a: diacylglycerol acyltransferase 1 (dgat-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to dgat-1 dysfunction or where modulation of dgat-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (type 1, type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as mycocardial, renal and liver fibrosis, hepatitis c virus infection and acne or other skin disorders.. .
Glaxosmithkline Llc






Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Roti for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Roti with additional patents listed. Browse our RSS directory or Search for other possible listings.


2.511

5073

3 - 0 - 101